TABLE 2.

Meta-regression analysis for the primary outcomes.

Variable	Coefficient	−95% CI	+95% CI	SE	p-value	Bubble plot
1-year OS
Median age	−0.039	−0.182	0.105	0.073	0.599	Supplementary Figure S4
Time to durvalumab	−0.017	−0.054	0.019	0.019	0.351	Supplementary Figure S5
ECOG PS 0%	0.006	−0.021	0.034	0.014	0.657	Supplementary Figure S6
PD-L1 <1%	−0.017	−0.043	0.009	0.013	0.193	Supplementary Figure S7
PD-L1 ≥50%	0.067	−0.004	0.138	0.036	0.064	Supplementary Figure S8
1-year PFS
Median age	0.028	−0.030	0.086	0.030	0.338	Supplementary Figure S12
Time to durvalumab	−0.001	−0.023	0.022	0.011	0.949	Supplementary Figure S13
ECOG PS 0%	0.017	0.002	0.033	0.008	0.026	Supplementary Figure S14
PD-L1 <1%	−0.009	−0.028	0.011	0.010	0.396	Supplementary Figure S15
PD-L1 ≥50%	0.312	−0.335	0.959	0.330	0.344	Supplementary Figure S16
All-grade pneumonitis
Median age	0.057	0.028	0.086	0.015	<0.001	Supplementary Figure S20
Time to durvalumab	−0.006	−0.011	−0.001	0.003	0.030	Supplementary Figure S21
ECOG PS 0%	−0.001	−0.010	0.007	0.004	0.747	Supplementary Figure S22
PD-L1 <1%	−0.001	−0.016	0.014	0.008	0.895	Supplementary Figure S23
PD-L1 ≥50%	−0.019	−0.033	−0.005	0.007	0.009	Supplementary Figure S24

SE, standard error; CI, confidence interval; PD-L1, programmed death-ligand 1; ECOG-PS, eastern cooperative oncology group performance status; OS, overall survival; DFS, disease free survival.

Significant values highlighted bold.